Exploratory testing - Insights
Mayo Clinic Laboratories’ whole exome and whole genome sequencing assays provide in-depth interrogation of all the genes in the human genome, offering individualized insights for optimal outcomes.
Invasive fungal infection - Insights
Mayo Clinic Laboratories’ fungal biomarker test rapidly screens for invasive fungal infections caused by various fungal pathogens.
Including carrier screening, molecular testing, and cytogenetic analysis, Mayo Clinic Laboratories prenatal evaluations provide vital insights for prospective and expecting parents.
Viral Hepatitis Testing - Mayo Clinic Laboratories
At Mayo Clinic, we utilize an algorithmic approach to testing that takes the guesswork out of test ordering to focus on proper test utilization, saving your institution time and money.
Neurodevelopmental disorders - Insights
Learn more about how chromosomal microarray can be used as a first-tier diagnostic test for those with congenital abnormalities and developmental disabilities.
Liquid biopsy offers noninvasive DNA testing for cancer care - Insights
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation...
Multiple Sclerosis Profile Updates - Insights
Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional...
Colorectal Cancer NGS Testing - Mayo Clinic Laboratories
Our panel was designed to meet current guidelines and remain targeted enough to provide clinically actionable results.
Neuromuscular disorders - Insights
Learn more about our specialized testing for neuromuscular diseases, including myasthenia gravis, Lambert-Eaton syndrome, and more.
Find out more about UBA1Q, a quantitative droplet digital polymerase chain reaction (ddPCR) assay that targets seven possible mutations that can occur in the UBA1 gene and help identify VEXAS syndrome.